Browsing by Subject "shortening"

Now showing 1 - 1 of 1
  • Thumbnail Image
    Item
    Telomere Shortening in the Alzheimer’s Disease Neuroimaging Initiative Cohort
    (IOS Press, 2019-09-03) Nudelman, Kelly N. H.; Lin, Jue; Lane, Kathleen A.; Nho, Kwangsik; Kim, Sungeun; Faber, Kelley M.; Risacher, Shannon L.; Foroud, Tatiana M.; Gao, Sujuan; Davis, Justin W.; Weiner, Michael W.; Saykin, Andrew J.; Initiative for the Alzheimer’s Disease Neuroimaging; Medical and Molecular Genetics, School of Medicine
    BACKGROUND: Although shorter telomeres have been associated with Alzheimer’s disease (AD), it is unclear whether longitudinal change in telomere length is associated with AD progression. OBJECTIVE: To investigate the association of telomere length change with AD diagnosis and progression. METHODS: In 653 individuals from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) cohort, T/S ratio (telomere vs. single copy gene), a proxy of telomere length, was measured for up to five visits per participant (N=1918 samples post-QC) using quantitative PCR (qPCR). T/S ratio was adjusted for batch effects and DNA storage time. A mixed effects model was used to evaluate association of telomere length with AD diagnostic group and interaction of age and diagnosis. Another mixed effects model was used to compare T/S ratio changes pre- to post-conversion to MCI or AD to telomere change in participants with stable diagnoses. RESULTS: Shorter telomeres were associated with older age (Effect Size (ES)=−0.23) and male sex (ES=−0.26). Neither baseline T/S ratio (ES=−0.036) nor T/S ratio change (ES=0.046) differed significantly between AD diagnostic groups. MCI/AD converters showed greater, but non-significant, telomere shortening compared to non-converters (ES=−0.186). CONCLUSIONS: Although AD compared to controls showed small, non-significant effects for baseline T/S ratio and T/S ratio shortening, we did observe a larger, though still non-significant effect for greater telomere shortening in converters compared to non-converters. Although our results do not support telomere shortening as a robust biomarker of AD progression, further investigation in larger samples and for subgroups of participants may be informative.